Safety of Atrovent® CFC‐free inhaler: respiratory events reported from an observational cohort study in England. (9th October 2017)

• Record Type: Journal Article
• Authors: Osborne, Vicki; Layton, Deborah; Fogg, Carole; Tong, Edward; Shakir, Saad A.W.
• Is Part Of: International journal of pharmacy practice. Volume 26:Number 4(2018)
• Page Start: 356
• Page End: 363
• Publication Date: 2017-10-09
• Subjects: Atrovent -- CFC‐free -- cohort -- respiratory -- safety; Pharmacy -- Practice -- Periodicals; 615.1
• DOI: 10.1111/ijpp.12407
• Languages: English
• ISSNs: 0961-7671

Abstract

Abstract: Objectives: The aim of the study was to identify any unexpected clinical events associated with starting the new CFC‐free formulation of Atrovent ® MDI in general practice in England. Methods: An active surveillance cohort study was conducted with a focus on selected clinical events, including respiratory symptoms, in past users of Atrovent ® CFC MDI ('switchers') and Atrovent ® naïve users. Incidence density rate ratios (with 99% confidence intervals) for events occurring in the first 3 months of exposure (risk period‐ID1‐3 ) compared to 3 months prior to starting treatment (reference period‐IDR ) were calculated. Results: The cohort consisted of 13 211 patients (median age 70 years, 50.1% female; 63.5% prior users of Atrovent ® CFC MDI ('switchers')). Common respiratory events occurred at higher rates after starting treatment than before for switchers, for example lower respiratory tract infection (LRTI) [ID1 /IDR = 1.45 (99% CI: 1.17, 1.81)] and worsening asthma [ID1 /IDR = 1.58 (99% CI: 1.00, 2.51)]. Of these events only LRTI was significant for Atrovent ® naïve patients [ID1 /IDR = 1.42 (99% CI: 1.04, 1.95)]. Conclusions: The results of this study suggest effect modification of risk as a result of prior Atrovent ® CFC MDI use. Overall, Atrovent ® CFC‐free MDI appeared to be reasonably well tolerated in the immediate postmarketing period and the safety profile appeared similar to that of the CFC formulation.